Psychedelic Therapy for Alcohol Use Disorder
Break Free from Addictive Patterns and Reclaim your Life with KARE: Ketamine for the Reduction of Alcohol Relapse.
As seen on Netflix’s “How to Change Your Mind”
When Standard Alcohol Use Disorder Treatments Fail to Deliver Results
Alcohol Use Disorder is a devastating condition that affects approximately 285 million people globally and results in more than 5% of all deaths.
In the U.S., only 8% of those suffering from Alcohol Use Disorders seek treatment[3], and 75% of them relapse within 12 months[4].
Through clinical trials, the KARE program has demonstrated that ketamine-assisted therapy has the potential to be more effective than any Alcohol Use Disorder treatment currently available.
The Power of Ketamine Therapy
Of days were abstinent for participants 6 months post-treatment with standard alcohol addiction recovery programs.
“After a crisis, I used alcohol to dampen my feelings. After my final ketamine journey, I had this feeling of joy, that I am enough—and it sticks. Nushama felt very safe.”
SUE ELLEN
nushama member
How Can Psychedelic-assisted Therapy Help with Alcohol Use Disorder?
If other treatments have failed to deliver lasting change, ketamine therapy offers an alternative approach to help you gain new perspectives, improve mental health, and make a fresh start.
The KARE program is intended to provide insights into the underlying cravings for alcohol and understand the deeply ingrained behavioral patterns that keep individuals stuck in cycles of substance dependency.
If other treatments have failed to deliver lasting change, ketamine therapy offers an alternative approach to help you gain new perspectives, improve mental health, and make a fresh start.
KARE is a structured, 4-week outpatient protocol that combines the power of psychedelic insights with rigorous psychotherapy.
How It Works
Our highly experienced clinicians deliver a 7-session program over 4 weeks in a safe, serene, therapeutic environment.
- All seven sessions include preparation, psychotherapy, and the integration of key insights gained during journeys, facilitating psychological breakthroughs and lasting behavioral change.
- Three of the seven sessions include IV ketamine journeys.
Most medications work by pharmacologically inducing a masking response, without addressing the underlying issue. Instead, ketamine provides a doorway into consciousness, so you can explore the root causes of addictive patterns, reframe your personal narrative, and gain powerful insights that can lead to a therapeutic breakthrough.
How Nushama’s Ketamine Therapy Compares with Traditional Alcohol Use Disorder Recovery Programs
Harness the Power of Psychedelic Therapy to Uncover the Root of Alcohol Use Disorder
Ketamine produces an ego-dissolving experience, so you can break free of your usual thought patterns and compassionately examine the underlying issues of your relationship with alcohol. When combined with therapy, this approach can lead to powerful breakthroughs that lead to lasting change.
Lower Cost & Greater Efficacy
Traditional rehab centers can cost $25,000-$50,000 per month or more, due to the extremely high costs of providing extended in-patient care. Our approach costs a fraction of traditional rehab with a much higher rate of success[1].
Greater Convenience
What is Ketamine?
Ketamine is a dissociative anesthetic that elicits psychedelic-like effects at certain doses. Ketamine-assisted therapy can be used as an alternative treatment for depression, anxiety, PTSD, and other mood disorders
Our Process - 7 Sessions Over 4 Weeks
Medical Assessment
Preparation
Psychedelic Treatment Sessions
The KARE program consists of 7 sessions over 4 weeks: 7 psychotherapy sessions, 3 of which involve ketamine journeys. Treatments take place in a serene environment with curated music. Your therapist will remain with you, and Nushama’s medical team will monitor you to ensure the highest level of safety.
Psychotherapy and Integration
Follow-up
$9,950 if paid in full or $788 for 12 months
(excluding medical intake and if approved by CareCredit)
Common Questions
What can I expect when I sign up?
You will be asked to complete a questionnaire to determine if you are eligible for the treatment. The eligibility criteria being met are a critical step in the process. We will then need your general practitioner’s records to ensure the eligibility criteria are correct. Our medical team will review this and then get in touch to either invite you in for an initial assessment or to inform you that, unfortunately, we will not be able to offer you this treatment.
Finally, the initial assessment will determine if psychedelic therapy is right for you. You will then be allocated to one of our clinics to undergo a 7-session course that includes preparation, integration, ketamine-assisted therapy, and psychotherapy, which will include three ketamine “dosing” sessions.
What is the evidence Ketamine-Assisted Therapy works?
The therapy and dosing regimen delivered in our clinics for people with alcohol problems was developed and tested through Awakn Life Sciences’ clinical trials for KARE (Ketamine in the Reduction of Alcoholic Relapse).
These trials showed ketamine-assisted therapy delivered 86% abstinence at 6 months post-treatment, significantly more than the approximate 25% abstinence in the standard treatment. Trial participants also experienced significant improvement in liver function and a substantial decrease in depression.
Anecdotally, many participants also reported sudden profound changes and ease of giving up after struggling for years. The results were published in the American Journal of Psychiatry in January 2022.
Because psychedelic-assisted therapy is effective at addressing underlying traumas that are linked to harmful repetitive thinking patterns, it presents the possibility of addressing a wide range of mental health issues rooted in trauma.
Click here for details of clinical trial outcomes.
What is the cost?
Is this covered by insurance?
- Awakn Announces Positive Results From Phase II A/B Clinical Trial, 2022
- Dakwar et al (2019). A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial
- National Institute for Health and Care Research, 2022
- National Institute on Alcohol Abuse and Alcoholism, 2022
Our Team & Advisors
Our team includes medical specialists in mood and eating disorders, alcohol use disorders, as well as leading researchers and practitioners in ketamine and other psychedelic therapies.
Dr. Julia Mirer is a psychedelic medicine advisor and advocate, bridging eastern and western practices, merging them to create a new paradigm for integrative health and wellness.
Eva Muschkin is a Nurse Practitioner who believes in a holistic approach to patient care, encompassing physical, emotional, social, and spiritual wellbeing. She worked in primary care prior but became more interested in how psychedelic medicine can benefit mental health.